Clik here to view.
Insulet sales grow 22% in Q1
Insulet (NSDQ:PODD) topped estimates on Wall Street yesterday with its first-quarter results, topping analysts’ sales expectations by $1.9 million. The Billerica, Mass.-based company reeled in its...
View ArticleClik here to view.
FDA chief suggests kickback laws could be used to rein in drug prices
Drug rebates paid between pharmaceutical companies and pharmacy benefit managers enjoy safe harbor status under federal kickback law, leaving them immune from legal scrutiny. But that could change, FDA...
View ArticleClik here to view.
Common Sensing, Haselmeier ink deal to develop connected injection pen
Swiss-based manufacturer Haselmeier inked a deal with Common Sensing to develop a smart, connected drug-delivery device for people who use injectable medications. The companies plan to combine...
View ArticleClik here to view.
J&J’s Janssen touts Ph3 data for antidepressant nasal spray
Johnson & Johnson‘s (NYSE:JNJ) Janssen revealed data today from two Phase III trials of its investigational esketamine nasal spray in patients with treatment-resistant depression. The Titusville,...
View ArticleClik here to view.
OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast...
OncoSec Medical (NSDQ:ONCS) expanded its relationship with Merck (NYSE:MRK) today, announcing a deal to combine its ImmunoPulse IL-12 device with Merck’s anti-PD-1 therapy, Keytruda, in a Phase II...
View ArticleClik here to view.
Takeda reaches $62B deal to buy Shire
After a series of offers, Takeda (TYO:4502) said today that it reached an agreement with Shire (NSDQ:SHPG) to acquire the U.S.-based company in a deal valued at $62 billion. The merger was approved by...
View ArticleClik here to view.
Medical device recalls significantly increase during Q1
The medical device and pharmaceutical industries saw a significant spike in product recalls during the first quarter of 2018, according to the U.S. Recall Index released by Stericycle Expert Solutions....
View ArticleClik here to view.
Pavmed registers for $20m rights offering
Pavmed (NSDQ:PAVM) said today that it filed a preliminary prospectus with the SEC for an offering of the rights to buy a new unit in exchange for each share of outstanding common stock. The medical...
View ArticleClik here to view.
How Bigfoot Biomedical’s CEO wants to boost diabetes management
Jeffrey Brewer faced the biggest challenge of his life when his 7-year-old son Sean received a diabetes diagnosis in 2002: Diabetes became the new focus for Brewer’s energy. In his role as CEO at JDRF...
View ArticleClik here to view.
Novartis paid $400K to consulting company linked to Trump attorney Michael Cohen
Novartis (NYSE:NVS) found itself in the middle of a national scandal today after it was revealed that the drugmaker made four payments that totaled nearly $400,000 to a consulting firm linked to...
View ArticleClik here to view.
Manufacturing delays lead to Epipen shortage in U.S.
At least 400 people across the U.S. have had trouble getting their hands on an Epipen in recent weeks, according to a survey from the advocacy group Food Allergy Research & Education. Mylan...
View ArticleClik here to view.
Mylan misses estimates on The Street with Q1 results
Shares in Mylan (NSDQ:MYL) rose slightly this morning after the pharmaceutical company reported its first-quarter financial results, missing analysts’ sales and earnings estimates. The company posted...
View ArticleClik here to view.
Trump’s drug pricing plan called ‘non-event’ by analysts
President Donald Trump last week unveiled his administration’s plan to lower drug prices. But investors seemed relieved after the president made his highly anticipated announcement – stocks for large...
View ArticleClik here to view.
Baxter wins FDA nod for Spectrum IQ infusion system
Baxter (NYSE:BAX) said today that it won FDA clearance for its Spectrum IQ infusion system with Dose IQ safety software. The company touted its system as the first of its kind to include bi-directional...
View ArticleClik here to view.
FDA seeks to bring clarity to combination product regulation
The FDA proposed a rule today that would amend regulations regarding the classification of products as biological products, devices, drugs or combination products. The agency said it hopes to modernize...
View ArticleClik here to view.
Boston Scientific’s drug-coated balloon succeeds in femoropopliteal segment...
Data from Boston Scientific‘s (NYSE:BSX) Ranger SFA trial showed that treatment with its drug-coated balloon succeeded in the femoropopliteal segment after one year and resulted in greater rates of...
View ArticleClik here to view.
Reva touts first implant of bioresorbable scaffold in Turkey
Reva Medical (ASX:RVA) said today that the company launched its Fantom bioresorbable scaffold in Turkey. There are nearly 100 hospitals performing cardiac catheterizations in Istanbul, according to...
View ArticleClik here to view.
HHS secretary calls on drug companies to ‘stop the price hikes’
After President Donald Trump’s drug pricing speech last week was deemed a “non-event” by analysts, all eyes turned to the secretary of the U.S. Dept. of Health & Human Services, Alex Azar, to see...
View ArticleClik here to view.
Medtronic launches study of drug-eluting stent as treatment for bifurcation...
Medtronic (NYSE:MDT) today launched a study to evaluate the safety and efficacy of its Resolute Onyx drug-eluting stent for the treatment of bifurcation lesions in patients with coronary artery...
View ArticleClik here to view.
FDA approves first non-opioid treatment for opioid withdrawal symptoms
The FDA today approved the first non-opioid treatment designed to help manage the symptoms of opioid withdrawal in adults. The drug, Lucemyra, isn’t a treatment for opioid use disorder, the agency...
View Article